tiprankstipranks
Trending News
More News >
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
US Market
Advertisement

Artiva Biotherapeutics, Inc. (ARTV) Stock Statistics & Valuation Metrics

Compare
46 Followers

Total Valuation

Artiva Biotherapeutics, Inc. has a market cap or net worth of $69.37M. The enterprise value is -$92.33M.
Market Cap$69.37M
Enterprise Value-$92.33M

Share Statistics

Artiva Biotherapeutics, Inc. has 24,425,762 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding24,425,762
Owned by Insiders7.25%
Owned by Institutions64.54%

Financial Efficiency

Artiva Biotherapeutics, Inc.’s return on equity (ROE) is -0.31 and return on invested capital (ROIC) is -32.85%.
Return on Equity (ROE)-0.31
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-32.85%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee2.61K
Profits Per Employee-680.97K
Employee Count96
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Artiva Biotherapeutics, Inc. is ―. Artiva Biotherapeutics, Inc.’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.61
Price to FCF
Price to Operating Cash Flow-0.98
PEG Ratio

Income Statement

In the last 12 months, Artiva Biotherapeutics, Inc. had revenue of 251.00K and earned -58.49M in profits. Earnings per share was -5.20.
Revenue251.00K
Gross Profit251.00K
Operating Income-67.28M
Pretax Income-58.49M
Net Income-58.49M
EBITDA-64.85M
Earnings Per Share (EPS)-5.20

Cash Flow

In the last 12 months, operating cash flow was -69.08M and capital expenditures -1.73M, giving a free cash flow of -70.81M billion.
Operating Cash Flow-69.08M
Free Cash Flow-70.81M
Free Cash Flow per Share-2.90

Dividends & Yields

Artiva Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.94
52-Week Price Change-72.62%
50-Day Moving Average2.44
200-Day Moving Average4.87
Relative Strength Index (RSI)59.45
Average Volume (3m)132.39K

Important Dates

Artiva Biotherapeutics, Inc. upcoming earnings date is Nov 18, 2025, After Close (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date

Financial Position

Artiva Biotherapeutics, Inc. as a current ratio of 15.39, with Debt / Equity ratio of 8.87%
Current Ratio15.39
Quick Ratio15.39
Debt to Market Cap0.03
Net Debt to EBITDA0.40
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Artiva Biotherapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Artiva Biotherapeutics, Inc. EV to EBITDA ratio is -1.35, with an EV/FCF ratio of -1.57.
EV to Sales349.04
EV to EBITDA-1.35
EV to Free Cash Flow-1.57
EV to Operating Cash Flow-1.59

Balance Sheet

Artiva Biotherapeutics, Inc. has $142.37M in cash and marketable securities with $13.22M in debt, giving a net cash position of -$129.14M billion.
Cash & Marketable Securities$142.37M
Total Debt$13.22M
Net Cash-$129.14M
Net Cash Per Share-$5.29
Tangible Book Value Per Share$16.58

Margins

Gross margin is 0.00%, with operating margin of -26805.58%, and net profit margin of -23303.98%.
Gross Margin0.00%
Operating Margin-26805.58%
Pretax Margin-23303.98%
Net Profit Margin-23303.98%
EBITDA Margin-25837.05%
EBIT Margin-26805.58%

Analyst Forecast

The average price target for Artiva Biotherapeutics, Inc. is $12.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.75
Price Target Upside303.48% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast
EPS Growth Forecast

Scores

Smart Score1
AI Score46
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis